Home/Filings/4/0001567619-20-000740
4//SEC Filing

Galligan Andrew H 4

Accession 0001567619-20-000740

CIK 0001444380other

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 12:00 PM ET

Size

8.2 KB

Accession

0001567619-20-000740

Insider Transaction Report

Form 4
Period: 2020-01-06
Galligan Andrew H
VP of Finance , CFO
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-01-062,78217,718 total
    Exercise: $63.23Exp: 2025-11-30Common Stock (2,782 underlying)
  • Exercise/Conversion

    Common Stock

    2020-01-06$63.23/sh+2,782$175,90656,272 total
  • Sale

    Common Stock

    2020-01-06$120.00/sh2,782$333,84053,490 total
Footnotes (3)
  • [F1]Includes 16,773 restricted stock units.
  • [F2]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  • [F3]Fully vested.

Documents

1 file

Issuer

NEVRO CORP

CIK 0001444380

Entity typeother

Related Parties

1
  • filerCIK 0001417976

Filing Metadata

Form type
4
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 12:00 PM ET
Size
8.2 KB